Samsara BioCapital, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001744967

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q3 2023 · 41 positions · Total reported value $326.68M · Top-10 concentration 69.6% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 37.0% · 3 new · 7 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q3 2023 13F filing, Samsara BioCapital, LLC disclosed 41 equity positions with a combined reported value of $326.68M. The filing implies a focused portfolio: its ten largest positions account for 69.6% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2023 were MLYS ($42.98M), RYZB ($40.98M), SRRK ($32.65M). By sector, the heaviest allocations are Health Care 43.6%, Industrials 1.1%.

Versus the prior quarter, Samsara BioCapital, LLC opened 3 new positions, trimmed 7 and fully exited 0, a turnover rate of 37.0% of positions.

The largest new positions opened in Q3 2023 were MLYS ($42.98M), RYZB ($40.98M), SRRK ($32.65M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2023)

  • MLYS MINERALYS THERAPEUTICS INC · $42.98M
  • RYZB RAYZEBIO INC · $40.98M
  • SRRK SCHOLAR ROCK HLDG CORP · $32.65M
  • SLRN ACELYRIN INC · $24.22M
  • ACLX ARCELLX INC · $22.03M
  • GRPH GRAPHITE BIO INC · $20.98M
  • ICPT INTERCEPT PHARMACEUTICALS IN · $11.88M
  • LYRA LYRA THERAPEUTICS INC · $10.87M

Fully Exited (vs previous quarter)

No tracked position was fully exited this quarter.

Insider Transactions (Form 4)

Latest Samsara BioCapital, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Samsara BioCapital, LLC files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 27 positions worth $1.05B in total. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • SEC registration: 801-113741 (status: Approved), registered 2018-07-27
  • Regulatory AUM (Form ADV): $2.17B as of 2026-10-28
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 3 private funds

Portfolio Structure

  • 27 positions · $1.05B reported value (Q3 2026)
  • Top 10 holdings = 87.9% of reported value
  • Largest position: SRRK (SCHOLAR ROCK HLDG CORP) at 31.7%
  • Average position size: $38.95M

Sector Tilt

  • Health Care 91.8%
  • Industrials 8.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 3 new, 3 added, 7 reduced
  • 14 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 43.6%
Technology 0.5%
Other 54.8%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 4.52M $42.98M 13.16%
13.16%
New
2 1.85M $40.98M 12.54%
12.54%
New
3 4.60M $32.65M 9.99%
9.99%
New
4 2.38M $24.22M 7.41%
7.41%
New
5 613.92K $22.03M 6.74%
6.74%
New
6 8.46M $20.98M 6.42%
6.42%
New
7 640.69K $11.88M 3.64%
3.64%
New
8 2.78M $10.87M 3.33%
3.33%
New
9 799.27K $10.75M 3.29%
3.29%
New
10 967.53K $9.97M 3.05%
3.05%
New
11 1.46M $9.25M 2.83%
2.83%
New
12 345.29K $7.92M 2.42%
2.42%
New
13 630.00K $7.09M 2.17%
2.17%
New
14 1.56M $6.56M 2.01%
2.01%
New
15 1.68M $5.81M 1.78%
1.78%
New
16 347.50K $5.66M 1.73%
1.73%
New
17 3.64M $5.13M 1.57%
1.57%
New
18 6.13M $5.11M 1.56%
1.56%
New
19 696.17K $4.77M 1.46%
1.46%
New
20 396.00K $4.59M 1.40%
1.40%
New
21 470.30K $4.49M 1.37%
1.37%
New
22 80.96K $4.20M 1.29%
1.29%
New
23 2.87M $3.99M 1.22%
1.22%
New
24 360.41K $3.63M 1.11%
1.11%
New
25 881.45K $3.48M 1.07%
1.07%
New
26 432.00K $3.45M 1.06%
1.06%
New
27 651.05K $3.31M 1.01%
1.01%
New
28 196.43K $2.41M 0.74%
0.74%
New
29 2.03M $1.75M 0.54%
0.54%
New
30 154.66K $1.29M 0.40%
0.40%
New
31 1.05M $1.09M 0.33%
0.33%
New
32 202.35K $1.02M 0.31%
0.31%
New
33 602.20K $831.04K 0.25%
0.25%
New
34 1.64M $781.77K 0.24%
0.24%
New
35 689.71K $717.30K 0.22%
0.22%
New
36 172.09K $390.64K 0.12%
0.12%
New
37 900.00K $360.00K 0.11%
0.11%
New
38 82.34K $177.02K 0.05%
0.05%
New
39 78.13K $101.57K 0.03%
0.03%
New
40 133.33K $13.33K 0.00%
0.00%
New
41 100.00K $4.11K 0.00%
0.00%
New

FAQ

What did Samsara BioCapital, LLC buy in 2023-Q3?

In its 2023-Q3 13F filing, Samsara BioCapital, LLC reported 41 equity positions worth $326.68M in aggregate; its largest disclosed positions were MLYS ($42.98M), RYZB ($40.98M), SRRK ($32.65M).

How large is Samsara BioCapital, LLC's portfolio?

Samsara BioCapital, LLC reported $326.68M of long equity holdings across 41 positions as of 2023-Q3. Top-10 holdings account for 69.6% of reported value.

What is Samsara BioCapital, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/samsara-biocapital/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →